SIGA reports Q3 product revenues $8.9M; receives $122M in procurement orders from US government

SIGA TECHNOLOGIES INC

2024-Q3 EPS reported $0.19 revenue$57,250,527

Product revenues $8.9M (Q3 2024) vs $8.0M YoY; total revenues $10.0M.
Net income of $1.3M ($0.02 diluted EPS) vs net loss of $0.4M in Q3 2023.
Received $122M in procurement orders, including $112.5M from BARDA for oral TPOXX to the SNS.
Special cash dividend of $0.60/share paid April 2024, up $0.15 from prior year.
Exclusive license from Vanderbilt for preclinical monoclonal antibodies targeting orthopoxviruses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.